Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal and intravenous paclitaxel plus S-1 for recurrent gastric cancer with peritoneal dissemination
jRCTs061200027Suspended
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel and tegafur in gastric adenocarcinoma and gastric cancer (GC). Primary endpoint: Progression-free survival. Started Apr 2021; status: suspended.
02
Drugs
paclitaxeltegafur
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on jRCTs061200027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200027.